Nordic Nanovector ASA (OSE: NANO), a company committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care, has reported its financial results for 2019, on Thursday.

Revenues for the full year 2019 were NOK0.0m, the same as last year.

The company reported total operating expenses for 2019 at NOK440.4m compared to NOK340m in 2018.

The firm posted comprehensive loss for 2019 at NOK433.3m compared to NOK336.8m in 2018.

Jan H Egberts, MD, chairman of Nordic Nanovector, commented: 'We currently have 47 patients enrolled in our pivotal PARADIGME Phase 2b trial evaluating Betalutin. The company will under its new management look into the current strategy and operational trial initiatives. We still aim to complete the patient enrolment in PARADIGME in the second half of 2020. The encouraging efficacy and safety profile demonstrated in the first part of the LYMRIT 37-01 Phase 1/2 trial with a single administration of Betalutin give the Board and management confidence in its potential to become an important option for patients with non-Hodgkin's lymphoma (NHL).'